Analysis reveals AI enhances drug discovery efficiencies, while highlighting data limitations and ethical concerns.
Artificial intelligence (AI) is revolutionizing drug discovery in medicine by enhancing precision, effectiveness, and creativity. Tools like virtual screening, de novo drug creation, and combinatorial QSAR and QSPR models are increasingly popular. This paper analyses AIdriven drug discovery, highlighting its shortcomings and potential. It addresses issues like moral dilemmas and limited data availability, suggesting solutions. The goal is to promote understanding of AI's potential and stimulate innovation in drug discovery procedures.
No takes yet. Share an insight, caveat, or question.
Priyadarshini et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: